4 Undervalued Pharmaceuticals Stocks for Wednesday, November 06
Discover the top 4 undervalued Pharmaceuticals stocks for Wednesday, November 06 based on AAII’s Stock Grades.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacturing, marketing, distribution, and sales of traditional Chinese medicine derivative products in China. The company offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. It also provides guben yanling, shenrong weisheng, and quanlu pill; yangxue danggui and qiangli pipa syrup; wuzi yanzong oral, fengtong medicinal, shenrong medicinal, qishe medicinal, fengshitong medicinal, and shiquan dabu medicinal liquor; paracetamol granule for children; and isatis root granule. In addition, the company distributes and sells third-party products, including biomedical drugs, medical instruments, traditional Chinese medicine pieces, and dietary supplements. It primarily serves pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was founded in 1998 and is headquartered in Ji'An, China. Universe Pharmaceuticals INC is a subsidiary of Sununion Holding Group Limited.
Commentary & Analysis
6 Undervalued Pharmaceuticals Stocks for Thursday, July 18
Discover the top 6 undervalued Pharmaceuticals stocks for Thursday, July 18 based on AAII’s Stock Grades.Jenna Brashear
7 Undervalued Pharmaceuticals Stocks for Tuesday, June 18
Discover the top 7 undervalued Pharmaceuticals stocks for Tuesday, June 18 based on AAII’s Stock Grades.Jack Gilleland
7 Undervalued Pharmaceuticals Stocks for Wednesday, May 01
Discover the top 7 undervalued Pharmaceuticals stocks for Wednesday, May 01 based on AAII’s Stock Grades.Eunice Kim
7 Undervalued Pharmaceuticals Stocks for Friday, January 26
Discover the top 7 undervalued Pharmaceuticals stocks for Friday, January 26 based on AAII’s Stock Grades.Eunice Kim
Financial Summary
| Share Statistics | UPC | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2.3 | $569.9 | 1% |
|
| Shares Out (Mil) | 0.6 | 44.8 | 3% |
|
| Institutional Ownership | 25.0% | 84.6% | 12% |
|
| Float (Mil) | 0.6 | 45.1 | 1% |
|
| Beta | 1.57 | 0.67 | 84% |
|
| Avg Daily Volume (000s) | 53 | 294 | 29% |
|
| Price Change (52-week) |
(13.4%) | 65.2% | 35% |
|
| Growth | UPC | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (10.2%) | 6.7% | 5% |
|
| Net Income (5yr) | (20.0%) | (2.0%) | 20% |
|
| EPS (5yr) | na | 14.9% | na |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (14.9%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | UPC | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $18 | $230 | 12% |
|
| Net Income (TTM) (Mil) | ($4) | ($11) | 35% |
|
| EPS (TTM) | ($8.055) | ($0.600) | 5% |
|
| Operating Cash Flow (TTM) (Mil) | ($5) | ($6) | 24% |
|
| Net Cash Flow (TTM) (Mil) | $7 | $4 | 55% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $7 | 0% |
|
| Enterprise Value (Q1) (Mil) | ($23) | $493 | 1% |
|
| Valuation | UPC | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.03 | 2.89 | 0% |
|
| P/E | na | 20.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | UPC | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 35.3% | 65.9% | 43% |
|
| Net Margin | (20.6%) | (0.2%) | 17% |
|
| ROA | (6.2%) | (25.5%) | 29% |
|
| ROE | (8.9%) | (21.4%) | 28% |
|
| Liabilities to Assets | 19.0% | 35.5% | 12% |
|
| F-Score | 4 | 3 | na |
|
Universe Pharmaceuticals INC did not pass any screens on 7/30/2026.
